JP2023535224A - 新規使用 - Google Patents

新規使用 Download PDF

Info

Publication number
JP2023535224A
JP2023535224A JP2023505377A JP2023505377A JP2023535224A JP 2023535224 A JP2023535224 A JP 2023535224A JP 2023505377 A JP2023505377 A JP 2023505377A JP 2023505377 A JP2023505377 A JP 2023505377A JP 2023535224 A JP2023535224 A JP 2023535224A
Authority
JP
Japan
Prior art keywords
alkyl
disease
disorder
glucagon
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535224A5 (enExample
Inventor
リ，ポン
キャス，デイビッド
デイビス，ロバート
スナイダー，グレッチェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2023535224A publication Critical patent/JP2023535224A/ja
Publication of JP2023535224A5 publication Critical patent/JP2023535224A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023505377A 2020-07-26 2021-07-26 新規使用 Pending JP2023535224A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063056706P 2020-07-26 2020-07-26
US63/056,706 2020-07-26
PCT/US2021/043230 WO2022026417A1 (en) 2020-07-26 2021-07-26 Novel uses

Publications (2)

Publication Number Publication Date
JP2023535224A true JP2023535224A (ja) 2023-08-16
JP2023535224A5 JP2023535224A5 (enExample) 2024-07-30

Family

ID=80036116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505377A Pending JP2023535224A (ja) 2020-07-26 2021-07-26 新規使用

Country Status (4)

Country Link
US (1) US20240009195A1 (enExample)
EP (1) EP4188353A4 (enExample)
JP (1) JP2023535224A (enExample)
WO (1) WO2022026417A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021035157A1 (en) * 2019-08-22 2021-02-25 Intra-Cellular Therapies, Inc. Organic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106547A1 (en) * 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2019152697A1 (en) * 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133261A2 (en) * 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
EP3010509B1 (en) * 2013-06-21 2021-07-28 Intra-Cellular Therapies, Inc. Free base crystals
DK3310784T3 (da) * 2015-06-17 2020-11-09 Pfizer Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
WO2017203229A1 (en) * 2016-05-27 2017-11-30 Cipla Limited Dapagliflozin premixes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106547A1 (en) * 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2019152697A1 (en) * 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ENDOCRINOLOGY, vol. 116(6):2251-2258, JPN6025030928, 1985, ISSN: 0005807509 *

Also Published As

Publication number Publication date
EP4188353A4 (en) 2024-07-03
EP4188353A1 (en) 2023-06-07
WO2022026417A1 (en) 2022-02-03
US20240009195A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
JP7571039B2 (ja) ピリダジノン及びその使用法
JP6360025B2 (ja) 有機化合物
RU2679142C2 (ru) Органические соединения
JP6804605B2 (ja) 有機化合物
JP6247249B2 (ja) 眼障害のためのｐｄｅ１阻害剤
KR20230058614A (ko) 암 치료를 위한 kat6 억제제 방법 및 조합
EP2485735B1 (en) Inhibitors of fatty acid binding protein (fabp)
US10398698B2 (en) Uses
US11166956B2 (en) Combinations of PDE1 inhibitors and NEP inhibitors
JP6696904B2 (ja) 製剤および医薬組成物
WO2018049417A1 (en) Novel uses
JP7543278B2 (ja) 有機化合物
JP2024504632A (ja) 非アルコール性脂肪肝疾患および関連する疾患または障害を処置または改善するための化合物、組成物および方法
US20240009195A1 (en) Novel uses
US12612395B2 (en) Rocaglate derivatives and uses thereof
US20220280517A1 (en) Organic compounds
EP2023921A1 (en) Inhibitor of adenylyl cyclase for treating a disorder of the circadian rhythm
JP2025532595A (ja) グリコーゲンシンターゼ１（ｇｙｓ１）の阻害剤としてのｎ－（ベンズヒドリル）シクロアルキルカルボキサミド誘導体及びその使用方法
JP2025532594A (ja) グリコーゲンシンターゼ１（ｇｙｓ１）の阻害剤としてのシクロアルキルカルボン酸誘導体及びその使用方法
JP2016130214A (ja) 糖尿病治療用医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260602